Article Details

Roche's PI3K inhibitor secures breakthrough status in breast cancer

Retrieved on: 2024-05-21 16:15:12

Tags for this article:

Click the tags to see associated articles and topics

Roche's PI3K inhibitor secures breakthrough status in breast cancer. View article details on hiswai:

Excerpt

Roche announced an FDA breakthrough therapy designation for its inavolisib/Ibrance combination therapy.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up